CORC

在结果中检索

CORC

浏览/检索结果: 共435条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Co-enhancement of oxidation resistance and mechanical properties of Cf/LAS composites: The effects of h-BN addition 会议论文
作者:  Wu, Songsong;  Dingd, Chuanyan;  Ma, Guansheng;  Xia, Long;  Hou, Yongzhao
收藏  |  浏览/下载：4/0  |  提交时间：2020/12/18
Tmem59 deletion ac vates microglia and reduces phagocytic capacity 会议论文
作者:  Kong, Yanyan;  Wang, Jiao;  Li, Jie;  Hua, Fengchun;  Zhao, Bizeng
收藏  |  浏览/下载：31/0  |  提交时间：2019/12/05
Tmem59 deletion activates microglia and reduces phagocytic capacity 会议论文
作者:  Kong, Yanvan;  Wang, Jiao;  Li, Jie;  Hua, Fengchun;  Zhao, Bizeng
收藏  |  浏览/下载：25/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
Classification of Schizophrenia Patients and Healthy Controls Using ICA of Complex-Valued fMRI Data and Convolutional Neural Networks 会议论文
16th International Symposium on Neural Networks, ISNN 2019, Moscow, Russia, 2019-07-10
作者:  Qiu, Yue;  Lin, Qiu-Hua;  Kuang, Li-Dan;  Zhao, Wen-Da;  Gong, Xiao-Feng
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/02
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：37/0  |  提交时间：2019/12/05
SIRCS: Slope-intercept-residual compression by correlation sequencing for multi-stream high variation data 会议论文
作者:  Ye, Zixin;  Hua, Wen;  Wang, Liwei;  Zhou, Xiaofang
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace